Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole
Phase 1CompletedDevelopment Stage
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
Feb 1, 2008 → Mar 1, 2008
About Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole
Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole is a phase 1 stage product being developed by Jazz Pharmaceuticals for Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4. The current trial status is completed. This product is registered under clinical trial identifier NCT01323465. Target conditions include Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01323465 | Phase 1 | Completed |
Competing Products
5 competing products in Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol Turbuhaler | AstraZeneca | Phase 1 | 33 |
| Avelox (Moxifloxacin, BAY12-8039) + Placebo | Bayer | Phase 1 | 30 |
| Sativex + Sativex + Sativex + Placebo + Marinol + Marinol | Jazz Pharmaceuticals | Phase 1 | 30 |
| ETC-1002 | Esperion Therapeutics | Phase 1 | 28 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |